Recommendations on switching or deprescribing hypnotic medications for insomnia

BACKGROUND: 10-30% of the world's population suffers from insomnia. One-quarter of those who take hypnotic medication become dependent on it. Given the wide variety of available drugs, switching them is complex. The existing recommendations do not cover all drug classes. There is a need for practical, evidence-based recommendations that take account of specific aspects of care both in Europe as a whole and regionally. METHODS: This narrative review is based on publications from May 1953 to February 2026 that were retrieved by a search in six English- and German-language databases, including guidelines, meta-analyses, systematic reviews, randomized controlled trials, and observational studies. Following the literature review, new recommendations were developed in a consensus process (consensus conference followed by the Delphi method) to supplement the current insomnia guideline. RESULTS: Treatment can be discontinued abruptly after short-term use (1-2 weeks) or if the drug in question does not produce withdrawal symptoms, e.g., daridorexant (an orexin receptor antagonist), melatonin, antihistamines, and phytotherapeutic drugs. Benzodiazepine receptor agonists, antidepressants, antipsychotics, and gabapentinoids should be tapered off gradually after medium- or long-term use (> 2 weeks), with a weekly dose reduction of 10-25%. Various gradual tapering methods can be used, depending on the drug, dose, duration of use, treatment regimen, and intended subsequent treatment. A longer taper is advisable after use at high doses (≥ 2/3 of the maximum dose) or over the long term (≥ 1 year). Withdrawal symptoms from benzodiazepine receptor agonists can be alleviated with the overlapping administration of daridorexant or eszopiclone. Cognitive behavioral therapy is recommended as an accompanying nonpharmacological treatment (relative risk [RR]: 1.68; 95% confidence interval: [1.19; 2.39]). CONCLUSION: A drug-specific approach with evidence-based and practice-oriented protocols should be used when hypnotic medications are switched or discontinued.

Authors

Publication Details

Journal
Deutsches Ärzteblatt international
Published
2026-09-10
DOI
https://doi.org/10.3238/arztebl.m2026.0141
Primary Topic
Sleep and related disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recommendations on switching or deprescribing hypnotic medications for insomnia

Yaroslav Winter, Christoph Schöbel, Ingo Fietze, Göran Hajak et al.
Deutsches Ärzteblatt international
Sleep and related disorders
article

Recommendations on switching or deprescribing hypnotic medications for insomnia

Yaroslav Winter, Christoph Schöbel, Ingo Fietze, Göran Hajak, Michael Saletu, Birgit Högl
article en

Abstract

BACKGROUND: 10-30% of the world's population suffers from insomnia. One-quarter of those who take hypnotic medication become dependent on it. Given the wide variety of available drugs, switching them is complex. The existing recommendations do not cover all drug classes. There is a need for practical, evidence-based recommendations that take account of specific aspects of care both in Europe as a whole and regionally. METHODS: This narrative review is based on publications from May 1953 to February 2026 that were retrieved by a search in six English- and German-language databases, including guidelines, meta-analyses, systematic reviews, randomized controlled trials, and observational studies. Following the literature review, new recommendations were developed in a consensus process (consensus conference followed by the Delphi method) to supplement the current insomnia guideline. RESULTS: Treatment can be discontinued abruptly after short-term use (1-2 weeks) or if the drug in question does not produce withdrawal symptoms, e.g., daridorexant (an orexin receptor antagonist), melatonin, antihistamines, and phytotherapeutic drugs. Benzodiazepine receptor agonists, antidepressants, antipsychotics, and gabapentinoids should be tapered off gradually after medium- or long-term use (> 2 weeks), with a weekly dose reduction of 10-25%. Various gradual tapering methods can be used, depending on the drug, dose, duration of use, treatment regimen, and intended subsequent treatment. A longer taper is advisable after use at high doses (≥ 2/3 of the maximum dose) or over the long term (≥ 1 year). Withdrawal symptoms from benzodiazepine receptor agonists can be alleviated with the overlapping administration of daridorexant or eszopiclone. Cognitive behavioral therapy is recommended as an accompanying nonpharmacological treatment (relative risk [RR]: 1.68; 95% confidence interval: [1.19; 2.39]). CONCLUSION: A drug-specific approach with evidence-based and practice-oriented protocols should be used when hypnotic medications are switched or discontinued.

Deutsches Ärzteblatt internationalVol. 123(19)
Good health and well-being
Openalex Percentile: Top 22%
Sleep and related disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.